GeneDx Corp. (WGS)
GeneDx Statistics
Share Statistics
GeneDx has 28.07M shares outstanding. The number of shares has increased by 5.44% in one year.
| Shares Outstanding | 28.07M |
| Shares Change (YoY) | 5.44% |
| Shares Change (QoQ) | 1.99% |
| Owned by Institutions (%) | 86.69% |
| Shares Floating | 24.51M |
| Failed to Deliver (FTD) Shares | 764 |
| FTD / Avg. Volume | 0.07% |
Short Selling Information
The latest short interest is 2.14M, so 7.78% of the outstanding shares have been sold short.
| Short Interest | 2.14M |
| Short % of Shares Out | 7.78% |
| Short % of Float | 9.69% |
| Short Ratio (days to cover) | 2.73 |
Valuation Ratios
The PE ratio is -39.53 and the forward PE ratio is 142.9. GeneDx's PEG ratio is 0.54.
| PE Ratio | -39.53 |
| Forward PE | 142.9 |
| PS Ratio | 6.77 |
| Forward PS | 5.3 |
| PB Ratio | 8.43 |
| P/FCF Ratio | -60.81 |
| PEG Ratio | 0.54 |
Enterprise Valuation
GeneDx Corp. has an Enterprise Value (EV) of 86.95M.
| EV / Earnings | -1.66 |
| EV / Sales | 0.28 |
| EV / EBITDA | -3.75 |
| EV / EBIT | -3.75 |
| EV / FCF | -2.56 |
Financial Position
The company has a current ratio of 3.61, with a Debt / Equity ratio of 0.26.
| Current Ratio | 3.61 |
| Quick Ratio | 3.42 |
| Debt / Equity | 0.26 |
| Total Debt / Capitalization | 20.76 |
| Cash Flow / Debt | -0.44 |
| Interest Coverage | 7.66 |
Financial Efficiency
Return on equity (ROE) is -0.21% and return on capital (ROIC) is -7.45%.
| Return on Equity (ROE) | -0.21% |
| Return on Assets (ROA) | -0.12% |
| Return on Capital (ROIC) | -7.45% |
| Revenue Per Employee | $305,450 |
| Profits Per Employee | $-52,286 |
| Employee Count | 1,000 |
| Asset Turnover | 0.73 |
| Inventory Turnover | 10.43 |
Taxes
| Income Tax | -343K |
| Effective Tax Rate | 0.01 |
Stock Price Statistics
The stock price has increased by 869.33% in the last 52 weeks. The beta is 1.98, so GeneDx's price volatility has been higher than the market average.
| Beta | 1.98 |
| 52-Week Price Change | 869.33% |
| 50-Day Moving Average | 87.12 |
| 200-Day Moving Average | 60.52 |
| Relative Strength Index (RSI) | 48.23 |
| Average Volume (20 Days) | 1.05M |
Income Statement
In the last 12 months, GeneDx had revenue of 305.45M and earned -52.29M in profits. Earnings per share was -1.94.
| Revenue | 305.45M |
| Gross Profit | 194.4M |
| Operating Income | -23.21M |
| Net Income | -52.29M |
| EBITDA | -23.21M |
| EBIT | -23.21M |
| Earnings Per Share (EPS) | -1.94 |
Balance Sheet
The company has 85.21M in cash and 64.25M in debt, giving a net cash position of 20.96M.
| Cash & Cash Equivalents | 85.21M |
| Total Debt | 64.25M |
| Net Cash | 20.96M |
| Retained Earnings | -1.35B |
| Total Assets | 419.38M |
| Working Capital | 143.15M |
Cash Flow
In the last 12 months, operating cash flow was -28.5M and capital expenditures -5.49M, giving a free cash flow of -33.99M.
| Operating Cash Flow | -28.5M |
| Capital Expenditures | -5.49M |
| Free Cash Flow | -33.99M |
| FCF Per Share | -1.26 |
Margins
Gross margin is 63.64%, with operating and profit margins of -7.6% and -17.12%.
| Gross Margin | 63.64% |
| Operating Margin | -7.6% |
| Pretax Margin | -17.23% |
| Profit Margin | -17.12% |
| EBITDA Margin | -7.6% |
| EBIT Margin | -7.6% |
| FCF Margin | -11.13% |
Dividends & Yields
WGS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -2.19% |
| FCF Yield | -1.37% |
Analyst Forecast
The average price target for WGS is $80, which is -9.6% lower than the current price. The consensus rating is "Strong Buy".
| Price Target | $80 |
| Price Target Difference | -9.6% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
Stock Splits
The last stock split was on May 4, 2023. It was a backward split with a ratio of 1:33.
| Last Split Date | May 4, 2023 |
| Split Type | backward |
| Split Ratio | 1:33 |
Scores
| Altman Z-Score | 5.38 |
| Piotroski F-Score | 4 |